About: Tabalumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company. A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.

Property	Value
dbo:abstract	Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company. A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint. (en)
dbo:casNumber	1143503-67-6
dbo:fdaUniiCode	PQP8VH3MJW
dbo:kegg	D10083
dbo:wikiPageID	33024217 (xsd:integer)
dbo:wikiPageLength	2970 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1073119161 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Rheumatoid_arthritis dbr:Eli_Lilly_and_Company dbr:B_cell dbc:Eli_Lilly_and_Company_brands dbr:Systemic_lupus_erythematosus dbr:B-cell_activating_factor
dbp:atcPrefix	none (en)
dbp:c	6518 (xsd:integer)
dbp:casNumber	1143503 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	10008 (xsd:integer)
dbp:kegg	D10083 (en)
dbp:mabType	mab (en)
dbp:n	1724 (xsd:integer)
dbp:o	2032 (xsd:integer)
dbp:s	38 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:B-cell_activating_factor
dbp:type	mab (en)
dbp:unii	PQP8VH3MJW (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	470476568 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Monoclonals_for_immune_system dbt:Monoclonal-antibody-stub
dcterms:subject	dbc:Eli_Lilly_and_Company_brands
gold:hypernym	dbr:Cell
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:AnatomicalStructure dbo:MonoclonalAntibody dbo:Drug
rdfs:comment	Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies. Tabalumab was developed by Eli Lilly and Company. A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013. In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint. (en)
rdfs:label	Tabalumab (en)
owl:sameAs	freebase:Tabalumab wikidata:Tabalumab https://global.dbpedia.org/id/4vavM
prov:wasDerivedFrom	wikipedia-en:Tabalumab?oldid=1073119161&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Tabalumab
is dbo:wikiPageWikiLink of	dbr:C6518H10008N1724O2032S38 dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_T–Td
is foaf:primaryTopic of	wikipedia-en:Tabalumab